Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 25;8(8):1606639.
doi: 10.1080/2162402X.2019.1606639. eCollection 2019.

Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors

Ahmad Hanif  1 , Manu Pandey  1 , Sumera Khan  2 , Kristopher Attwood  3 , Saby George  1
Affiliations

Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors

Ahmad Hanif et al. Oncoimmunology. .

Abstract

Introduction: Renal cell carcinoma (RCC) with sarcomatoid component carries a poor prognosis. Immune checkpoint inhibitors (CPIs) have been approved for the treatment of metastatic RCC, but their efficacy in patients with sarcomatoid component is not known. Materials and Methods: We conducted a retrospective chart review of 30 consecutive patients at our center who were treated for metastatic RCC with sarcomatoid component. Results: Ten patients were treated with CPI group while 20 patients were in No-CPI group. There were no significant differences in age, sex, race, and stage at diagnosis between the two groups. After a median follow-up of 35 months, 3 of 10 patients in CPI arm and 5 of 20 patients in No-CPI group were alive. The median overall survival was 33.8 m in immunotherapy group compared to 8.8 m in nonimmunotherapy group (p = .001). Discussion: In our experience, CPI therapy resulted in better outcomes compared to traditional therapy with molecular-targeted agents or chemotherapy in these patients.

Keywords: Immunotherapy; kidney cancer; nivolumab; renal cell carcinoma; sarcomatoid.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival between patients who received therapy with immune checkpoint inhibitors (CPI) and those who did not (No CPI).
See this image and copyright information in PMC

References

    1. Chow W-H, Dong LM, Devesa SS.. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010. May;7(5):245–257. doi:10.1038/nrurol.2010.184. - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2018. CA Cancer J Clin. 2018. January;68(1):7–30. doi:10.3322/caac.21442. - DOI - PubMed
    1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet Lond Engl. 2008. August 9;372(9637):449–456. doi:10.1016/S0140-6736(08)61039-9. - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009. August 1;27(22):3584–3590. doi:10.1200/JCO.2008.20.1293. - DOI - PMC - PubMed
    1. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010. February 20;28(6):1061–1068. doi:10.1200/JCO.2009.23.9764. - DOI - PubMed

Publication types

LinkOut - more resources